Sur180 Therapeutics, INC

10:30 AM - 10:45 AM (EDT), Tuesday, June 6, 2023 ・ Session Room 104B
Sur180 Therapeutics is changing the way endometriosis pain and progression are treated. We are re-introducing drugs tested for safety but never commercialized for their original intent. While all current endometriosis therapies target the gonadal system, we focus on the stress system, which has intimate crosstalk with female gonads. The company is strongly positioned to decrease chronic pelvic pain and endometriosis recurrence, resulting in millions of dollars in savings associated with repeated surgeries and productivity loss in women with endometriosis. Sur180 Therapeutics plans to use a direct-to-Phase II approach for testing our drug against endometriosis.
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Pain Management
Lead Product in Development:
A small molecule that antagonizes the corticotrophin-releasing hormone receptor type 1.
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Co-Founder and CEO
Sur180 Therapeutics, INC